| Literature DB >> 33905016 |
Tarek Jazmati1,2, Axel Hamprecht1,2,3, Nathalie Jazmati4,5,6.
Abstract
To establish the optimal detection of third-generation cephalosporin-resistant Enterobacterales (3GCREB), the performance of four different screening methods has been investigated: stool samples without (A) and with (B) pre-enrichment and rectal swabs without (C) and with (D) pre-enrichment were contrasted. Pre-enrichment approaches (B and D) increased the detection of 3GCREB carriers by 29.4% (20/68 3GCREB carriers only found using pre-enrichment, p < 0.0001) compared to direct plating approaches (A and C). Moreover, the study demonstrates a minor advantage of stool samples in contrast to rectal swabs in both cases (with and without pre-enrichment). Registration number: DRKS00022520, 24 July 2020.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33905016 PMCID: PMC8520522 DOI: 10.1007/s10096-021-04250-1
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Fig. 1Flow chart study design and description of sample flow
Comparisons of the different algorithms for the detection of 3GCREB carriers by using McNemar
| Stool without pre-enrichment (A) | Stool with pre-enrichment (B) | Rectal swab without pre-enrichment (C) | Rectal swab with pre-enrichment (D) | Stool total (A + B) | Rectal swab total (C + D) | |
|---|---|---|---|---|---|---|
| Stool without pre-enrichment (A)a | X | X | 98.3/0.6875 | X | X | X |
| Stool with pre-enrichment (B)a | 95.5/0.0042 | X | 94.9/0.0013 | 93.8/0.8318 | X | 93.8/1 |
| Rectal swab without pre-enrichment (C)a | X | X | X | X | X | X |
| Rectal swab with pre-enrichment (D)a | 95.5/0.0213 | X | 95.5/0.0042 | X | X | X |
| Stool total (A + B)a | 96.1/0.0001 | 99.4/0.5 | 94.9/0.0001 | 93.8/0.5235 | X | 93.8/0,8318 |
| Rectal swab total (C + D)a | 95.5/0.0042 | 93.8/1 | 96.1/0.0001 | 99.4/0.5 | X | X |
The approach with the better performance is in each comparison located in the slot on the left side
aOverall percent agreement (%)/p value
Sensitivities, specificities, PPVs and NPVs of the four different algorithms for the detection of 3GCREB tested on 478 clinical specimens
| Detection target (3GCREB or ESBL-E) Samples considered and used detection algorithm | No. of samples | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) | Prevalence, % (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
| TPa | FPb | FNc | ||||||
| Detection of 3GCREB | ||||||||
| All growth consideredd | ||||||||
| Stool without pre-enrichment (A) | 60 | 46 | 27 | 69.0 (58.0–78.2) | 88.2 (84.5–91.2) | 56.6 (46.6–66.1) | 92.7 (89.5–95.1) | 18.2 (14.9–22.0) |
| Stool with pre-enrichment (B) | 72 | 52 | 15 | 82.8 (72.8–89.7) | 86.7 (82.8–89.8) | 58.1 (48.9–66.8) | 95.8 (93.0–97.5) | 18.2 (14.9–22.0) |
| Rectal swab without pre-enrichment (C) | 58 | 29 | 29 | 66.7 (55.7–76.2) | 92.6 (89.4–94.9) | 66.7 (55.7–76.2) | 92.6 (89.4–94.9) | 18.2 (14.9–22.0) |
| Rectal swab with pre-enrichment (D) | 70 | 50 | 17 | 80.5 (70.3–87.9) | 87.2 (83.4–90.3) | 58.3 (49.0–67.2) | 95.3 (92.4–97.1) | 18.2 (14.9–22.0) |
| Stool total (A + B) | 75 | 64 | 12 | 86.2 (76.8–92.4) | 83.6 (79.5–87.1) | 54.0 (45.3. - 62.4) | 96.5 (93.7–98.1) | 18.2 (14.9–22.0) |
| Rectal swab total (C + D) | 74 | 52 | 13 | 85.1 (75.4–91.5) | 86.7 (82.8–89.8) | 58.7 (49.6–67.3) | 96.3 (93.6–97.9) | 18.2 (14.9–22.0) |
| Selected growth considerede | ||||||||
| Stool without pre-enrichment (A) | 60 | 25 | 27 | 69.0 (58.0–78.2) | 93.6 (90.6–95.7) | 70.6 (59.6–79.7) | 93.1 (90.0–95.3) | 18.2 (14.9–22.0) |
| Stool with pre-enrichment (B) | 72 | 20 | 15 | 82.8 (72.8–89.7) | 94.9 (92.1–96.8) | 78.3 (68.2–85.9) | 96.1 (93.5–97.7) | 18.2 (14.9–22.0) |
| Rectal swab without pre-enrichment (C) | 58 | 15 | 29 | 66.7 (55.7–76.2) | 96.2 (93.6–97.8) | 79.5 (68.1–87.7) | 92.8 (89.8–95.1) | 18.2 (14.9–22.0) |
| Rectal swab with pre-enrichment (D) | 70 | 13 | 17 | 80.5 (70.3–87.9) | 96.7 (94.2–98.1) | 84.3 (74.3–91.1) | 95.7 (93.1–97.4) | 18.2 (14.9–22.0) |
| Stool total (A + B) | 75 | 29 | 12 | 86.2 (76.8–92.4) | 92.6 (89.4–94.9) | 72.1 (62.3–80.2) | 96.8 (94.3–98.3) | 18.2 (14.9–22.0) |
| Rectal swab total (C + D) | 74 | 17 | 13 | 85.1 (75.4–91.5) | 95.7 (93.0–97.4) | 81.3 (71.5–88.4) | 96.6 (94.2–98.1) | 18.2 (14.9–22.0) |
| Detection of ESBL-E | ||||||||
| All growth consideredd | ||||||||
| Stool without pre-enrichment (A) | 42 | 64 | 6 | 87.5 (74.1–94.8) | 85.1 (81.3–88.3) | 39.6 (30.4–49.6) | 98.4 (96.3–99.3) | 10.0 (7.6–13.2) |
| Stool with pre-enrichment (B) | 44 | 80 | 4 | 91.7 (79.1–97.3) | 81.4 (77.3–84.9) | 35.5 (27.2–44.6) | 98.9 (96.9–99.6) | 10.0 (7.6–13.2) |
| Rectal swab without pre-enrichment (C) | 40 | 47 | 8 | 83.3 (69.2–92.0) | 89.1 (85.6–91.8) | 46.0 (35.4–57.0) | 98.0 (95.8–99.0) | 10.0 (7.6–13.2) |
| Rectal swab with pre-enrichment (D) | 41 | 79 | 7 | 85.4 (71.6–93.5) | 81.6 (77.6–85.1) | 34.2 (25.9–43.5) | 98.0 (95.8–99.1) | 10.0 (7.6–13.2) |
| Stool total (A + B) | 46 | 93 | 2 | 95.8 (84.6–99.3) | 78.4 (74.1–82.1) | 33.1 (25.5–41.6) | 99.4 (97.7–99.9) | 10.0 (7.6–13.2) |
| Rectal swab total (C + D) | 43 | 83 | 5 | 89.6 (76.6–96.1) | 80.7 (76.6–84.3) | 34.1 (26.1–43.2) | 98.6 (96.5–99.5) | 10.0 (7.6–13.2) |
| Selected growth considerede | ||||||||
| Stool without pre-enrichment (A) | 42 | 43 | 6 | 87.5 (74.1–94.8) | 90.0 (86.7–92.6) | 49.4 (38.5–60.4) | 98.5 (96.5–99.4) | 10.0 (7.6–13.2) |
| Stool with pre-enrichment (B) | 44 | 48 | 4 | 91.7 (79.1–97.3) | 88.8 (85.4–91.6) | 47.8 (37.4–58.4) | 99.0 (97.2–99.7) | 10.0 (7.6–13.2) |
| Rectal swab without pre-enrichment (C) | 40 | 33 | 8 | 83.3 (69.2–92.0) | 92.3 (89.3–94.6) | 54.8 (42.8–66.3) | 98.0 (96.0–99.1) | 10.0 (7.6–13.2) |
| Rectal swab with pre-enrichment (D) | 41 | 42 | 7 | 85.4 (71.6–93.5) | 90.2 (86.9–92.8) | 49.4 (38.3–60.5) | 98.2 (96.2–99.2) | 10.0 (7.6–13.2) |
| Stool total (A + B) | 46 | 58 | 2 | 95.8 (84.6–99.3) | 86.5 (82.8–89.5) | 44.2 (34.6–54.3) | 99.5 (97.9–99.9) | 10.0 (7.6–13.2) |
| Rectal swab total (C + D) | 43 | 48 | 5 | 89.6 (76.6–96.1) | 88.8 (85.4–91.6) | 47.3 (36.8–57.9) | 98.7 (96.8–99.5) | 10.0 (7.6–13.2) |
A combined gold standard consisting of all four approaches was applied for the calculation
aTP, true positive. A result was considered TP when at least one 3GCREB isolate was recovered from the sample
bFP, false positive. A result was considered FP when the isolate(s) recovered from the sample was not confirmed to be a 3GCREB
cFN, false negative
dWhen no selection criteria were applied (for calculation, all oxidase positive/negative and all colored/uncolored colonies growing on ESBL agar were counted)
eWhen selection criteria were applied (only oxidase negative and colored colonies growing on ESBL agar were counted)
Isolate characteristics of 3GCREB isolates recovered by all 4 algorithms
| Strain characteristics | Overall ( | 3GCREB isolates recovered by | |||||
|---|---|---|---|---|---|---|---|
| Stool without pre-enrichment (A) ( | Stool with pre-enrichment (B) ( | Rectal swab without pre-enrichment (C) ( | Rectal swab with pre-enrichment (D) ( | Without pre-enrichment total (A + C) ( | With pre-enrichment total (B + D) ( | ||
| Species 3GCREB | |||||||
| | 45 (46.4%) | 42 (61.8%) | 41 (50.6%) | 37 (58.7%) | 37 (49.3%) | 42 (59.2%) | 43 (45.7%) |
| | 11 (11.3%) | 6 (8.8%) | 11 (13.6%) | 5 (8.0%) | 7 (9.3%) | 7 (9.9%) | 11 (11.7%) |
| | 12 (12.4%) | 8 (11.8%) | 11 (13.6%) | 9 (14.3%) | 11 (14.7%) | 9 (12.7%) | 12 (12.8%) |
| | 25 (25.8%) | 10 (14.7%) | 15 (18.5%) | 9 (14.3%) | 18 (24.0%) | 10 (14.1%) | 25 (26.6%) |
| | 4 (4.1%) | 2 (2.9%) | 3 (3.7%) | 3 (4.8%) | 2 (2.7%) | 3 (4.2%) | 3 (3.2%) |
| Resistance mechanism | |||||||
| ESBL (no. (%)) | 54 (55.7%) | 47 (69.1%) | 49 (60.5%) | 43 (68.3%) | 44 (58.7%) | 49 (69.0%) | 52 (55.3%) |
| CTX-M-1 (no. (% of ESBL)) | 33 (61.1%) | 30 (63.8%) | 31 (63.3%) | 29 (67.4%) | 28 (63.6%) | 32 (65.3%) | 32 (61.5%) |
| CTX-M-9 (no. (% of ESBL)) | 9 (16.7%) | 7 (14.9%) | 8 (16.3%) | 6 (14.0%) | 8 (18.2%) | 7 (14.3%) | 9 (17.3%) |
| Unknown ESBL mechanism | 12 (22.2%) | 10 (21.3%) | 10 (20.4%) | 8 (18.6%) | 8 (18.2%) | 10 (20.4%) | 11 (21.2%) |
| AmpC (no. (%)) | 36 (37.1%) | 15 (22.1%) | 25 (30.9%) | 15 (23.8%) | 26 (34.7%) | 16 (22.5%) | 35 (37.2%) |
| Hyper K1 (no. (%)) | 1 (1.0%) | 1 (1.5%) | 1 (1.2%) | 1 (1.6%) | 1 (1.3%) | 1 (1.4%) | 1 (1.1%) |
| VIM carbapenemase (no. (%)) | 2 (2.1%) | 1 (1.5%) | 2 (2.5%) | 1 (1.6%) | 1 (1.3%) | 1 (1.4%) | 2 (2.1%) |
| IMP carbapenemase (no. (%)) | 2 (2.1%) | 2 (2.9%) | 2 (2.5%) | 2 (3.2%) | 2 (2.7%) | 2 (2.8%) | 2 (2.1%) |
| SHV-1 (no. (%)) | 2 (2.1%) | 2 (2.9%) | 2 (2.5%) | 1 (1.6%) | 1 (1.3%) | 2 (2.8%) | 2 (2.1%) |
3GCREB, third-generation cephalosporin-resistant Enterobacterales
ESBL-E, extended-spectrum-beta-lactamase-producing Enterobacterales
If an Isolate harboured more than one resistance mechanism, it was classified in the highest resistance mechanism (carbapenemase > ESBL > AmpC > Hyper K1/SHV-1)